RemovedRisk Factors
Examples of regulatory changes that can affect our business, beyond direct changes to Medicare reimbursement rates, can be found from time to time in CMS’s annual rulemaking. For example, the final rule for the fiscal year 2010 IRF-PPS implemented new coverage requirements which provided in part that a patient medical record must document a reasonable expectation that, at the time of admission to an IRF, the patient generally required and was able to participate in the intensive rehabilitation therapy services uniquely provided at IRFs. CMS has also taken the position that a patient’s medical file must appropriately document the rationale for the use of group therapies, as opposed to one-on-one therapy. Beginning in 2015, CMS instituted a new data collection requirement pursuant to which IRFs must capture the minutes and mode (individual, group, concurrent, or co-treatment) of therapy by specialty. Additionally, from time to time CMS has adopted changes in the medical conditions that will presumptively count toward the 60% compliance threshold to qualify for reimbursement as an inpatient rehabilitation hospital.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedRisk Factors
President Trump has issued an unprecedented number of executive orders during his first 30 days in office. Many call for changes in policy or practice at federal agencies as well as additional rulemaking to further the policy ends. Given the amount of revenues we receive from Medicare and Medicaid, an extensive number of changes in federal policy affecting a broad spectrum of business operations, including by means of executive orders affecting parties doing business with the federal government, may increase our compliance costs and potential liability in the event of noncompliance.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedRisk Factors
In December 2020, HHS-OCR proposed a new rule that would modify HIPAA regulations. According to HHS-OCR, the proposed rule is intended to promote care coordination and value-based care. The proposed changes to the HIPAA rules also provide for strengthening individuals’ rights to access their own health information, including electronic information; improving information sharing for care coordination and case management for individuals; facilitating greater family and caregiver involvement in the care of individuals experiencing emergencies or health crises; enhancing flexibilities for disclosures in emergency or threatening circumstances, such as the opioid and COVID-19 public health emergencies; and reducing administrative burdens on HIPAA covered healthcare providers and health plans, while continuing to protect individuals’ health information privacy interests. Although one of the stated purposes of the proposed rules is to reduce healthcare providers burdens, providers would have to engage in a number of activities to come into compliance if the changes are finalized, including changing policies and procedures, changing patient privacy notices and business associate agreements and training workforce members in the new requirements.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedRisk Factors
than federal, international or other state laws, and such laws may conflict with each other, which significantly complicates compliance efforts.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedRisk Factors
We expend significant capital to protect against cybersecurity threats, including denial of service attacks, email phishing schemes, hacking, advanced persistent threats, malware, and ransomware. Substantial additional expenditures may be required to respond to and remediate any problems caused by breaches, including the unauthorized access to or theft of patient data and protected health information stored in our information systems and the introduction of computer malware or
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedRisk Factors
expand our operations in those states. For a breakdown of the CON status of the states and territories in which we have operations, see Item 2, Properties.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedRisk Factors
•limitations in obtaining financing for acquisitions at a cost reasonable to us;
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RewordedRisk Factors
The proper function, availability, and security of our information systems are critical to our business and Our failure to maintain proper function, availability, recruit and retain qualified clinical personnel, or security of to control our information systems or protect our data against unauthorized access staffing costs, could have a material adverse effect on our business, financial position, results of operations, and cash flows.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
We monitor legal developments in data privacy and security regulations at the local, state and federal level, however, the regulatory framework for data privacy and security worldwide is continuously evolving and developing and, as a result, interpretation and implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
For example, the ACA provides for the expansion of expanded the federal Anti-Kickback Law and the False Claims Act (the “FCA”) that, when combined with other recent federal initiatives, are likely to increase investigation and enforcement efforts increasing compliance scrutiny in the healthcare industry generally.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
See Note 9, Long-term Debt, to the accompanying consolidated financial statements, the “Liquidity and Capital Resources” section of Item 7, Management’s Discussion and Analysis of Financial Condition and Results of Operations, and Item 2, Properties. Note 8, Long-term Debt, to the accompanying consolidated financial statements.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
Certain state laws may be more stringent or broader in scope, or offer greater individual rights, with respect to confidential, sensitive and personal information than federal, international or other state laws, and such laws may conflict with each other, which significantly complicates compliance efforts.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
In accordance with Medicare laws and federal statutes, CMS makes market an annual adjustment to Medicare reimbursement rates, commonly known as a “market basket updates update,” by provider type in an effort to compensate providers for rising operating costs.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
We cannot predict what the antitrust policy of the Trump administration will be, but continued agressive Continued aggressive federal enforcement of antitrust laws would likely increase the time, effort, and expense associated with acquisitions and may ultimately make it less likely to consummate acquisitions.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
Substantial damages, fines, or other remedies assessed against us or agreed to in settlements could have a material adverse effect on our business, financial position, results of operations, and cash flows, including indirectly as a result of the covenant defaults under our credit agreement or debt instruments or other claims such as those in securities actions.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
However, CMS holds the acute-care hospital where a joint replacement takes place accountable for the quality and costs of care for the entire episode of care — from the time of the original admission through 90 days after discharge.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
Enforcement of Noncompliance with ONC’s and CMS’ new health information access, exchange, and use standards began in 2021, and noncompliance access rules can result in civil monetary penalties, exclusion from participation in federal health care programs and other appropriate “disincentives,” including reductions in Medicare reimbursements.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
In a June 2018 2023 report mandated by the IMPACT Act, MedPAC reiterated its recommendation that reviewed the considerations associated with Congress adopt designing and adopting a unified payment system for all Medicare post-acute care (a “PAC-PPS”) in lieu of separate systems for inpatient rehabilitation facilities (“IRFs”), skilled nursing facilities, long-term acute-care hospitals, and home health agencies.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
MedPAC previously estimated, although we cannot verify the methodology or the accuracy of that estimate, a PAC-PPS would result in a 15% reduction in IRF reimbursements. reimbursements and shift aggregate reimbursements from for-profit and freestanding IRFs to non-profit and hospital-based IRFs.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
Some adverse consequences are may not be insurable, such as reputational harm and third-party business interruption.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
Our employees are also may be at greater risk of contracting contagious diseases due to their increased exposure to vulnerable patients.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
On July 4, 2025, President Trump signed into law the One Big Beautiful Bill Act (“OBBBA”). The OBBBA contains a range of healthcare-related provisions impacting coverage, financing, and provider reimbursement in state Medicaid programs. These provisions include enrollee work requirements, limitations on states’ ability to assess provider taxes to increase federal matching Medicaid funds, and limitations on states’ directed payments to providers. Most of these provisions take effect in 2027 or later and likely require additional federal and state regulatory action to implement. The OBBBA includes other non-healthcare specific, tax-related items. For further discussion of these items, see Note 14, Income Taxes, to the accompanying consolidated financial statements of this report, and the “Results of Operations” section of this Item.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
The OBBBA contained a broad range of tax reform provisions affecting businesses. While tax changes in the OBBBA did not have a material impact on our effective tax rate, certain tax provisions in the OBBBA, namely the provision that permanently extended bonus depreciation for certain assets placed in service after January 19, 2025 and the provision allowing for immediate expensing of certain research and development costs, resulted in current deductions that yielded lower cash income tax for 2025. We currently estimate these provisions produced an additional approximately $84 million in current deductions resulting in approximately $22 million in cash tax savings in 2025. Our cash payments for income taxes approximated $124 million and $164 million, net of refunds, in 2025 and 2024, respectively. These payments were based on estimates of taxable income. The 2025 payments included estimates of the tax provisions contained in the OBBBA. In 2025 and 2024, current income tax expense was $170.6 million and $139.5 million, respectively.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
We continue to evaluate the tax and other provisions of the OBBBA and the potential effects on our financial position, results of operations, and cash flows. The OBBBA includes other non-tax specific, healthcare-related items. For further discussion of the OBBBA, see Item 1, Business, and Item 1A, Risk Factors, “Reimbursement Risks.”
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
recognizing that these actions may increase our leverage ratio. See also the “Authorizations for Returning Capital to Stakeholders” section of this Item.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
events and their effects cannot be determined with certainty, actual results could differ from our assumptions and estimates, and such differences could be material.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RemovedMD&A
Under the IRF RCD, participating IRFs have an initial choice between pre-claim or post-payment review of 100% of Medicare claims submitted to demonstrate compliance with applicable requirements during the first six-month review period or cycle. We elected the pre-claim review option for our IRFs in Alabama for the first cycle. Under the pre-claim review choice, services can begin prior to the submission of the review request and continue while the decision is being made. The pre-claim review request with required documentation must be submitted, reviewed, and approved before the final claim is paid. If a certain percentage of the claims reviewed are found to be valid, the IRF may then opt out of the 100% review. The opt-out validation percentages for the second and third cycles were 85% or greater and 90% or greater, respectively. In opting out, the IRF may elect spot prepayment reviews of samples consisting of 5% of total claims or selective post-payment review of a statistically valid random sample. Our claim validation rate for the first cycle ending in February 2024 exceeded the required 80% at our IRFs in Alabama. For the second cycle, which began on May 1, 2024, we elected not to opt out, so our IRFs in Alabama remained subject to the 100% pre-claim review. None of our IRFs in Alabama achieved the 85% claim validation rate for the second cycle ending in October 2024. We believe many of the non-affirmations in the second cycle were based on application of improper standards or requirements that directly conflict with the Medicare coverage criteria for IRFs. In the third cycle, we are again submitting 100% of review requests pre-claim. We have engaged, and will continue to engage, with the MAC and CMS to ensure the review process is consistent with existing rules, regulations and statutes. Given the inconsistent review process applied by the MAC across the previous two cycles, we cannot predict the impact, if any, IRF RCD may have on the collectability of our Medicare claims over its five-year term and ultimately our financial position, results of operations, and cash flows.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
In order to meet our clinical staffing needs, we have continued to utilize third-party agencies and to pay sign-on and shift bonuses to our employees. While the costs associated with these actions have declined compared to the prior year, future costs will be affected by labor market conditions and other factors.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
Depreciation and amortization increased during 2024 compared to 2023 due to our capital investments throughout 2023 and 2024. Depreciation and amortization in 2023 included $6.1 million related to the accelerated amortization of the remaining carrying value of certificate of need (“CON”) assets in South Carolina. In May 2023, the governor of South Carolina signed into law S.164, which repealed the requirement of certain healthcare providers to obtain and/or maintain a CON.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
Effective July 1, 2024, we expanded our existing joint venture with Piedmont Healthcare (“Piedmont”), which we control, by contributing the assets and operations of our previously wholly-owned 70-bed hospital in Augusta, Georgia. Piedmont contributed approximately $90 million on July 1, 2024, which indirectly resulted in Piedmont obtaining a 50% ownership interest in the hospital. For additional information, see Note 1, Summary of Significant Accounting Policies, “Noncontrolling Interests in Consolidated Affiliates,” to the accompanying consolidated financial statements.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RewordedMD&A
Discharge growth from new stores during 2024 2025 compared to 2023 2024 resulted from our joint ventures in Knoxville, Tennessee (March 2023), Owasso, Oklahoma (March 2023), Bowie, Maryland (June 2023), Columbus, Georgia (September 2023), Atlanta, Georgia (May 2024), and Louisville, Kentucky (June 2024), Athens, Georgia (March 2025), and Fort Myers, Florida (May 2025), as well as our wholly owned hospitals in Clermont, Florida (April 2023), Prosper, Texas (November 2023), Fitchburg, Wisconsin (November 2023), Kissimmee, Florida (May 2024), Johnston, Rhode Island (July 2024), and Fort Mill, South Carolina (September 2024). 2024), Houston, Texas (November 2024), and Daytona Beach, Florida (July 2025).
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
For the Year Ended December 31, 2025 2024 2023 2022 Net cash provided by operating activities $ 1,175.6 $ 1,002.8 $ 850.8 $ 705.8 Interest expense and amortization of debt discounts and fees 123.2 137.4 143.5 175.7 Gain (loss) on sale of investments, excluding impairments 5.9 2.7 4.6 (15.5) Equity in net income of nonconsolidated affiliates 4.3 3.0 3.2 2.9 Net income attributable to noncontrolling interests in continuing operations (192.9) (140.9) (111.0) (93.6) Amortization of debt-related items (9.6) (9.7) (9.5) (9.7) Distributions from nonconsolidated affiliates (4.1) (4.0) (1.6) (4.0) Current portion of income tax expense 170.6 139.5 128.3 72.2 Change in assets and liabilities (4.3) (21.9) (50.3) 30.4 Cash used in (provided by) operating activities of discontinued operations 1.4 3.1 16.0 (52.3) Asset impairment impact on noncontrolling interests — (7.3) — — State regulatory change impact on noncontrolling interests — — (2.2) — Change in fair market value of equity marketable securities (2.5) (1.0) (0.7) 7.4 Other 0.3 — — Adjusted EBITDA $ 1,267.9 $ 1,103.7 $ 971.1 $ 819.3
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
For the Year Ended December 31, 2025 2024 2023 2022 Net income $ 759.1 $ 596.6 $ 463.0 $ 365.9 Loss (income) from discontinued operations, net of tax, attributable to Encompass Health 1.0 2.8 12.0 (15.2) Net income attributable to noncontrolling interests included in continuing operations (192.9) (140.9) (111.0) (93.6) Provision for income tax expense 192.9 150.2 132.2 100.1 Interest expense and amortization of debt discounts and fees 123.2 137.4 143.5 175.7 Loss on early extinguishment of debt — 0.6 — 1.4 Loss on disposal or impairment of assets 2.7 17.4 9.8 4.8 Depreciation and amortization 327.9 299.6 273.9 243.6 Stock-based compensation 56.5 48.3 50.6 29.2 State regulatory change impact on noncontrolling interests — — (2.2) — Change in fair market value of equity marketable securities (2.5) (1.0) (0.7) 7.4 Asset impairment impact on noncontrolling interests — (7.3) — — Adjusted EBITDA $ 1,267.9 $ 1,103.7 $ 971.1 $ 819.3
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
Salaries and benefits decreased as a percent of Net operating revenues during 2024 2025 compared to 2023 2024 primarily due to higher volumes a decline in EPOB and provider tax revenues decreases in both contract labor and lower revenue reserves related to bad debt as discussed above. sign-on and shift bonuses.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
General and administrative expenses decreased increased in terms of dollars and as a percent of Net operating revenues during 2024 2025 compared to 2023 2024 primarily due to higher volumes. incentive compensation and costs associated with our transition to a new enterprise resource planning system, Oracle Fusion, in 2025.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
The increase in Net income attributable to noncontrolling interests during 2024 2025 compared to 2023 2024 primarily resulted from increased profitability from certain existing joint venture hospitals partially offset by the ramp up of new joint venture hospitals and the impact from the impairment related to the closure of our joint venture hospital in Eau Claire, Wisconsin in February 2024, as discussed above. hospitals.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
The increase in Net income attributable to noncontrolling interests during 2024 compared to 2023 primarily resulted from increased profitability from certain existing joint venture hospitals partially offset by the ramp up of new joint venture hospitals and included the impact from the impairment related to the closure of our joint venture hospital in Eau Claire, Wisconsin in February 2024, as discussed above.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
The increase in Net cash used in financing activities of continuing operations during 2024 2025 compared to 2023 2024 primarily resulted from lower Contributions from noncontrolling interests of consolidated affiliates and higher net debt payments and repurchases of common stock partially offset by higher Contributions from noncontrolling interests of consolidated affiliates. lower net debt payments.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
Consistent with these objectives, in August and November 2024, September 2025, we redeemed $150 the remaining $100 million and $100 million, respectively, of the outstanding principal balance of our 5.75% Senior Notes due 2025 (the “2025 Notes”) at maturity using cash on hand. hand and capacity under our revolving credit facility.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
Other operating expenses decreased increased in terms of dollars and as a percent of Net operating revenues during 2024 2025 compared to 2023 2024 primarily due to increased provider tax expense, as discussed above, and higher volumes. costs resulting from development activities.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
The decrease in Interest expense and amortization of debt discounts and fees in 2024 2025 compared to 2023 2024 primarily resulted from the September 2025, November 2024, and August and November 2024 redemptions of $100 million, $100 million, and $150 million and $100 million, respectively, in outstanding principal amount of the Company’s 5.75% Senior Notes due 2025. 2025 (the “2025 Notes”).
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
See Note 9, Long-term Debt, 1, Summary of Significant Accounting Policies, “Noncontrolling Interests in Consolidated Affiliates,” to the accompanying consolidated financial statements, for additional information related to our debt. on this transaction.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new